Literature DB >> 21447777

A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1.

Edwin S Iversen1, Fergus J Couch, David E Goldgar, Sean V Tavtigian, Alvaro N A Monteiro.   

Abstract

BACKGROUND: Besides revealing cancer predisposition variants or the absence of any changes, genetic testing for cancer predisposition genes can also identify variants of uncertain clinical significance (VUS). Classifying VUSs is a pressing problem, as ever more patients seek genetic testing for disease syndromes and receive noninformative results from those tests. In cases such as the breast and ovarian cancer syndrome in which prophylactic options can be severe and life changing, having information on the disease relevance of the VUS that a patient harbors can be critical.
METHODS: We describe a computational approach for inferring the disease relevance of VUSs in disease genes from data derived from an in vitro functional assay. It is based on a Bayesian hierarchical model that accounts for sources of experimental heterogeneity.
RESULTS: The functional data correlate well with the pathogenicity of BRCA1 BRCT VUSs, thus providing evidence regarding pathogenicity when family and genetic data are absent or uninformative.
CONCLUSIONS: We show the utility of the model by using it to classify 76 VUSs located in the BRCT region of BRCA1. The approach is both sensitive and specific when evaluated on variants previously classified using independent sources of data. Although the functional data are very informative, they will need to be combined with other forms of data to meet the more stringent requirements of clinical application. IMPACT: Our work will lead to improved classification of VUSs and will aid in the clinical decision making of their carriers. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447777      PMCID: PMC3111818          DOI: 10.1158/1055-9965.EPI-10-1214

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  22 in total

1.  A full-likelihood method for the evaluation of causality of sequence variants from family data.

Authors:  Deborah Thompson; Douglas F Easton; David E Goldgar
Journal:  Am J Hum Genet       Date:  2003-07-29       Impact factor: 11.025

2.  Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.

Authors:  Marcelo A Carvalho; Sylvia M Marsillac; Rachel Karchin; Siranoush Manoukian; Scott Grist; Ramona F Swaby; Turan P Urmenyi; Edson Rondinelli; Rosane Silva; Luis Gayol; Lisa Baumbach; Rebecca Sutphen; Jennifer L Pickard-Brzosowicz; Katherine L Nathanson; Andrej Sali; David Goldgar; Fergus J Couch; Paolo Radice; Alvaro N A Monteiro
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

3.  Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.

Authors:  Georgia Chenevix-Trench; Sue Healey; Sunil Lakhani; Paul Waring; Margaret Cummings; Ross Brinkworth; Amie M Deffenbaugh; Lynn Anne Burbidge; Dmitry Pruss; Thad Judkins; Tom Scholl; Anna Bekessy; Anna Marsh; Paul Lovelock; Ming Wong; Andrea Tesoriero; Helene Renard; Melissa Southey; John L Hopper; Koulis Yannoukakos; Melissa Brown; Douglas Easton; Sean V Tavtigian; David Goldgar; Amanda B Spurdle
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

4.  Population-Calibrated Gene Characterization: Estimating Age at Onset Distributions Associated With Cancer Genes.

Authors:  Edwin S Iversen; Sining Chen
Journal:  J Am Stat Assoc       Date:  2005       Impact factor: 5.033

5.  Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.

Authors:  J Vallon-Christersson; C Cayanan; K Haraldsson; N Loman; J T Bergthorsson; K Brøndum-Nielsen; A M Gerdes; P Møller; U Kristoffersson; H Olsson; A Borg; A N Monteiro
Journal:  Hum Mol Genet       Date:  2001-02-15       Impact factor: 6.150

6.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.

Authors:  S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas
Journal:  J Med Genet       Date:  2005-07-13       Impact factor: 6.318

7.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

8.  Classification of BRCA1 missense variants of unknown clinical significance.

Authors:  C M Phelan; V Dapic; B Tice; R Favis; E Kwan; F Barany; S Manoukian; P Radice; R B van der Luijt; B P M van Nesselrooij; G Chenevix-Trench; T Caldes; M de la Hoya; S Lindquist; S V Tavtigian; D Goldgar; A Borg; S A Narod; A N A Monteiro
Journal:  J Med Genet       Date:  2005-02       Impact factor: 6.318

9.  Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.

Authors:  Megan S Lee; Ruth Green; Sylvia M Marsillac; Nicolas Coquelle; R Scott Williams; Telford Yeung; Desmond Foo; D Duong Hau; Ben Hui; Alvaro N A Monteiro; J N Mark Glover
Journal:  Cancer Res       Date:  2010-06-01       Impact factor: 12.701

10.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Authors:  Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

View more
  27 in total

Review 1.  Annotating individual human genomes.

Authors:  Ali Torkamani; Ashley A Scott-Van Zeeland; Eric J Topol; Nicholas J Schork
Journal:  Genomics       Date:  2011-08-02       Impact factor: 5.736

Review 2.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.

Authors:  D M Eccles; G Mitchell; A N A Monteiro; R Schmutzler; F J Couch; A B Spurdle; E B Gómez-García
Journal:  Ann Oncol       Date:  2015-07-07       Impact factor: 32.976

3.  Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.

Authors:  Vanessa C Fernandes; Volha A Golubeva; Giuliano Di Pietro; Cara Shields; Kwabena Amankwah; Thales C Nepomuceno; Giuliana de Gregoriis; Renata B V Abreu; Carly Harro; Thiago T Gomes; Ricceli F Silva; Guilherme Suarez-Kurtz; Fergus J Couch; Edwin S Iversen; Alvaro N A Monteiro; Marcelo A Carvalho
Journal:  J Biol Chem       Date:  2019-02-14       Impact factor: 5.157

4.  Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.

Authors:  Lucia Guidugli; Hermela Shimelis; David L Masica; Vernon S Pankratz; Gary B Lipton; Namit Singh; Chunling Hu; Alvaro N A Monteiro; Noralane M Lindor; David E Goldgar; Rachel Karchin; Edwin S Iversen; Fergus J Couch
Journal:  Am J Hum Genet       Date:  2018-01-25       Impact factor: 11.025

Review 5.  Genomic Biomarkers for Breast Cancer Risk.

Authors:  Michael F Walsh; Katherine L Nathanson; Fergus J Couch; Kenneth Offit
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

6.  Two decades after BRCA: setting paradigms in personalized cancer care and prevention.

Authors:  Fergus J Couch; Katherine L Nathanson; Kenneth Offit
Journal:  Science       Date:  2014-03-28       Impact factor: 47.728

7.  Predicting the Pathogenic Potential of BRCA1 and BRCA2 Gene Variants Identified in Clinical Genetic Testing.

Authors:  Clare Brookes; Stella Lai; Elaine Doherty; Donald R Love
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

Review 8.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

Review 9.  Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation.

Authors:  Alvaro N Monteiro; Peter Bouwman; Arne N Kousholt; Diana M Eccles; Gael A Millot; Jean-Yves Masson; Marjanka K Schmidt; Shyam K Sharan; Ralph Scully; Lisa Wiesmüller; Fergus Couch; Maaike P G Vreeswijk
Journal:  J Med Genet       Date:  2020-03-09       Impact factor: 6.318

10.  Consequences of germline variation disrupting the constitutional translational initiation codon start sites of MLH1 and BRCA2: Use of potential alternative start sites and implications for predicting variant pathogenicity.

Authors:  Michael T Parsons; Phillip J Whiley; Jonathan Beesley; Mark Drost; Niels de Wind; Bryony A Thompson; Louise Marquart; John L Hopper; Mark A Jenkins; Melissa A Brown; Kathy Tucker; Linda Warwick; Daniel D Buchanan; Amanda B Spurdle
Journal:  Mol Carcinog       Date:  2013-12-02       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.